Key Takeaways RVTY projects Q2 revenues of $700M-$715M and EPS of $1.13-$1.15 amid tariff-related margin pressure.RVTY's Diagnostics gains are driven by immunodiagnostics strength and Genomics England collaboration.RVTY's Life Sciences growth is led by Signals Software, offsetting weak academic demand for instruments.Revvity, Inc. (RVTY) is slated to report second-quarter 2025 results on July 28, before market open.In the last reported quarter, the company delivered an earnings surprise of 5.21%. RVTY’s ear ...